Estimating the Risks and Benefits of Tamoxifen for Prophylactic Breast Cancer Chemoprevention in Korea

PURPOSE: According to the National Surgical Adjuvant Breast and Bowel Project P1 (NSABP-P1) study, tamoxifen can prevent 49% of invasive breast cancers in patients who have a 5-year risk of 1.67% or more. Because tamoxifen is associated with both adverse effects (endometrial cancer, stroke, pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong Uk, Min, Jun Won, Kim, You-Me, Chang, Myung-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318174/
https://www.ncbi.nlm.nih.gov/pubmed/22493628
http://dx.doi.org/10.4048/jbc.2012.15.1.51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318174/
https://www.ncbi.nlm.nih.gov/pubmed/22493628
http://dx.doi.org/10.4048/jbc.2012.15.1.51

Ejemplares similares